1. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002 15:337–49.
2. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2002 27:2396–408.
3. Tannoury CA, An HS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J 2014 14:552–9.
4. Papakostidis C, Kontakis G, Bhandari M, Giannoudis PV. Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results. Spine (Phila Pa 1976) 2008 33:E680–92.
5. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 2005 87:1205–12.
6. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006 31:2534–9.
7. Agarwal R, Williams K, Umscheid CA, Welch WC. Osteoinductive bone graft substitutes for lumbar fusion: a systematic review. J Neurosurg Spine 2009 11:729–40.
8. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002 27:2662–73.
9. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages: definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976) 2000 25:376–81.
10. Haid RW Jr, Branch CL Jr, Alexander JT, Burkus JK. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004 4:527–38.
11. Cammisa FP Jr, Lowery G, Garfin SR, et al. Twoyear fusion rate equivalency between Grafton DBM gel and autograft in posterolateral spine fusion: a prospective controlled trial employing a side-byside comparison in the same patient. Spine (Phila Pa 1976) 2004 29:660–6.
12. Carreon LY, Glassman SD, Anekstein Y, Puno RM. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Spine (Phila Pa 1976) 2005 30:E243–6.
13. Jenis LG, Banco RJ, Kwon B. A prospective study of autologous growth factors (AGF) in lumbar interbody fusion. Spine J 2006 6:14–20.
14. Sassard WR, Eidman DK, Gray PM, et al. Augmenting local bone with Grafton demineralized bone matrix for posterolateral lumbar spine fusion: avoiding second site autologous bone harvest. Orthopedics 2000 23:1059–64.
15. Vaccaro AR, Stubbs HA, Block JE. Demineralized bone matrix composite grafting for posterolateral spinal fusion. Orthopedics 2007 30:567–70.
16. Vaccaro AR, Whang PG, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 2008 8:457–65.
17. Bess S, Line BG, Lafage V, et al. Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use?: a prospective, multicenter study of 279 consecutive patients. Spine (Phila Pa 1976) 2014 39:233–42.
18. Lubelski D, Abdullah KG, Steinmetz MP, et al. Adverse events with the use of rhBMP-2 in thoracolumbar and lumbar spine fusions: a 9-year institutional analysis. J Spinal Disord Tech 2015 28:E277–83.
19. Mok JM, Durrani SK, Piper SL, et al. Extravasation of rhBMP-2 with use of postoperative drains after posterolateral spinal fusion. Spine (Phila Pa 1976) 2008 33:1668–74.
20. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006 31:542–7.
21. Wanderman NW, Carlson B, Freedman BA. Tranexamic acid (TXA) in thoracic and lumbar fusions and perioperative blood loss. In: Proceedings of the 59th Society of Military Orthopaedic Surgeons Annual Meeting; 2017 Dec 11-15; Scottsdale, USA. Towson (MD). Society of Military Orthopaedic Surgeons. 2018
22. Owens K, Glassman SD, Howard JM, Djurasovic M, Witten JL, Carreon LY. Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion. Eur Spine J 2011 20:612–7.